Compare TG Therapeutics Inc (TGTX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs WD 40 Company — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while WD 40 Company trades at $231.66 (market cap $3.13B). The key difference: TG Therapeutics Inc is far larger — about 2.4× WD 40 Company's market cap, and WD 40 Company pays a 1.75% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WDFC | |
|---|---|---|
Market Cap | $7.64B | $3.13B |
Sector | Health | Technology |
52-Week High | $59.06 | $264.91 |
52-Week Low | $26.94 | $187.52 |
Enterprise Value | $7.84B | $3.18B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
WDFC trades at $232.50, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue is projected to grow to $675 million in 2026, though net income may dip slightly. A dividend of $1.02 per share is payable July 31, 2026.
Outlook is mixed: solid brand strength and cash flow support stability, but high valuation ratios and margin pressures pose risks. Analyst consensus is cautious with 71% hold ratings. Key catalysts include execution against growth strategy, while headwinds include cost inflation and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
